Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

CP-675,206 In Patients With Advanced Melanoma

ClinicalTrials.gov ID: NCT00086489

Public ClinicalTrials.gov record NCT00086489. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 3, 2026, 11:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 1 Open Label, Non-Randomized, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Immune Function Effects, And Efficacy Of Multiple Doses Of CP-675,206 In Patients With Advanced Melanoma, And Phase 2, Open Label, Randomized Study To Evaluate the Efficacy, Safety, Tolerability And Pharmacokinetics Of 2 Regimens Of CP-675,206 In Patients With Advanced Melanoma.

Study identification

NCT ID
NCT00086489
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
AstraZeneca
Industry
Enrollment
118 participants

Conditions and interventions

Interventions

  • CP-675,206 Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2003
Primary completion
Apr 30, 2007
Completion
Apr 30, 2009
Last update posted
Jun 5, 2012

2003 – 2009

United States locations

U.S. sites
9
U.S. states
7
U.S. cities
7
Facility City State ZIP Site status
Research Site Los Angeles California 90095
Research Site Tampa Florida 33612
Research Site Chicago Illinois 60637-1460
Research Site Ann Arbor Michigan 48109-0008
Research Site Ann Arbor Michigan 48109-0843
Research Site Pittsburgh Pennsylvania 15232-1305
Research Site Pittsburgh Pennsylvania 15232
Research Site Nashville Tennessee 37232
Research Site Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00086489, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 5, 2012 · Synced May 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00086489 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →